Vanda's iloperidone not-approvable in US - update
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals' investigational antipsychotic iloperidone, its lead drug candidate, has received a not-approvable letter from theUS FDA, causing the US biotech's shares to plummet 73% on Nasdaq, closing at $0.90 on July 28th.